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Classic Parkinson’s disease (PD) is characterized by
fibrillar a-synuclein inclusions known as Lewy bodies
in the substantia nigra, which are associated with ni-
grostriatal degeneration. However, a-synuclein pa-
thologies accumulate throughout the CNS in areas
that also undergo progressive neurodegeneration,
leading to dementia and other behavioral impairments
in addition to parkinsonism. Although mutations in
the a-synuclein gene only cause Lewy body PD in
rare families, and although there are multiple other,
albeit rare, genetic causes of familial parkinsonism,
sporadic Lewy body PD is the most common
movement disorder, and insights into mechanisms
underlying a-synuclein-mediated neurodegeneration
provide novel targets for the discovery of disease-
modifying therapies for PD and related neurodegener-
ative a-synucleinopathies.
Introduction
Long before the description of Parkinson’s disease (PD)
by James Parkinson nearly 200 years ago, there were
accounts of a clinical syndrome consisting of tremor
and akinesia described in Indian medical (Ayurvedic)
texts written >3000 years ago (Manyam, 1990; Kat-
zenschlager et al., 2004). Remarkably, this syndrome,
termed kampavata in Sanskrit, was treated with natural
products from Mucuna pruriens, a plant now known to
contain levodopa (L-dopa), the symptomatic drug inter-
vention that revolutionized PD therapy in the mid-20th
Century. However, our understanding of mechanisms
underlying the onset and progression of PD is undergo-
ing a second, more profound revolution initiated by the
identification of mutations in the gene encoding a-synu-
clein (SNCA) and the demonstration that a-synuclein is
the principal component of filamentous Lewy bodies
(Polymeropoulos et al., 1997; Spillantini et al., 1997).
Indeed, these and subsequent insights into the normal
biology and function of a-synuclein and the role of a-
synuclein pathologies in PD are reorienting the design
of drug discovery efforts to focus on targets related to
a-synuclein misfolding and fibrillization into filamentous
Lewy bodies and Lewy neurites, as well as other poten-
tial pathogenic pathways involving a-synuclein oxida-
tion/nitration and degradation (Cookson, 2005; Feany,
2004; Forman et al., 2005; Giasson et al., 2004b; Savitt
et al., 2006). Thus, clarity about the relationship of a-syn-
uclein-mediated neurodegenerative mechanisms to PD
*Correspondence: vmylee@mail.med.upenn.eduwill have a powerful impact on the development of dis-
ease-modifying therapies for PD and related disorders
characterized by a-synuclein pathologies. Here we re-
view recent advances in understanding the role of path-
ologically altered forms of a-synuclein in the onset and
progression of PD, as well as the implications thereof
for developing novel disease-modifying therapies for
PD and related neurodegenerative disorders that are
characterized neuropathologically by abundant accu-
mulations of a-synuclein inclusions throughout the
central nervous system (CNS). (Note that due to the ex-
plosive growth in new information on the genetic and
molecular pathology of PD, only limited recent primary
publications are listed, and earlier literature is available
in reviews cited here.)
a-Synuclein and Lewy Body Parkinson’s Disease
The most common neurodegenerative movement disor-
der is Lewy body PD, which is know to increase progres-
sively with advancing age such that it affects about 1%
of individuals who are 65 years of age, but 5% or more of
those individuals 85 years of age and older. Lewy body
PD is characterized clinically by L-dopa-responsive mo-
tor impairments that include (1) bradykinesia, (2) in-
creased muscle tone, (3) resting tremor, and (4) abnor-
mal postural righting reflexes, although it is well known
that the clinical phenotype of Lewy body PD overlaps
with other new and previously described forms of par-
kinsonism (Forman et al., 2005; Giasson et al., 2004b;
Savitt et al., 2006). Although there was considerable
skepticism about the existence of a genetic etiology of
PD throughout the 20th Century, these doubts were dis-
pelled following the report of the first pathogenic SNCA
mutation in familial PD in 1997. Since then, over a dozen
additional genes and genetic loci have been implicated
as causes of Lewy body PD or other familial Parkinson
syndromes. Thus, as reviewed elsewhere (Feany, 2004;
Forman et al., 2005; Giasson et al., 2004b; Savitt et al.,
2006), there are multiple, seemingly unrelated genetic
causes of nigrostriatal degeneration that manifest as
parkinsonism, with and without Lewy bodies. And, while
familial PD caused by a-synuclein mutations is ex-
tremely rare, PD characterized by a-synuclein contain-
ing Lewy bodies accounts for >90% of sporadic Parkin-
sonian disorders (Feany, 2004; Forman et al., 2005;
Savitt et al., 2006).
Normal a-Synuclein and Its Putative Function
a-Synuclein is an abundant, 140 amino acid long, highly
soluble neuronal cytoplasmic protein that is, for the
most part, unstructured in aqueous solution. It is pre-
dominantly localized to presynaptic terminals in the
CNS, where it is loosely associated with synaptic vesi-
cles (Cookson, 2005; Giasson et al., 2004b; Savitt
et al., 2006). While the exact functions of normal a-syn-
uclein remain to be fully elucidated, studies in songbirds
suggest it may play a role in synaptic plasticity, and data
obtained from studies of a-synuclein knockout mice,
though controversial, indicate that this synaptic pro-
tein may be involved in activity-dependent negative
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of synaptic vesicle pools. Furthermore, a recent genetic
study in mice suggests that a-synuclein may function as
a cochaperone with cystein-string protein a in protect-
ing nerve terminals against injury (Chandra et al.,
2005). Finally, other recent studies suggest that a-synu-
clein may be involved in the trafficking of cargoes within
the endoplasmic reticulum/Golgi network since one of
the most profound initial consequences of overexpress-
ing a-synuclein in yeasts appears to be a disruption of
this trafficking (Cooper, et al., 2006).
a-Synuclein is a member of a family of three synaptic
proteins that include a-synuclein, b-synuclein, and g-
synuclein. While the members of the synuclein family
share considerable sequence homology, a-synuclein is
unique in that it contains a highly amyloidogenic domain
within its midregion that, by itself, fibrillizes more readily
than the holoprotein (Giasson et al., 2004b). Indeed, this
may explain why a-synuclein is the only member of the
synuclein family to form fibrillar structures in vitro. Of
the other synuclein family members, b-synuclein is the
most closely related to a-synuclien, and it also shows
a highly overlapping subcellular pattern of expression
within the CNS, localizing to presynaptic nerve termi-
nals. Although the functions of the other members of
the synuclein protein family are equally enigmatic, there
is evidence that the expression of b-synuclein may reg-
ulate the levels or metabolism of a-synuclein, since b-
synuclein inhibits a-synuclein aggregation in transgenic
mice (Hashimoto et al., 2001). Furthermore, more recent
studies indicate that increased expression of b-synu-
clein can decrease the levels of a-synuclein by mecha-
nisms that do not appear to affect a-synuclein mRNA
levels (Fan et al., 2006), but it is likely that the functions
of b-synuclein extend beyond regulating the expression
of a-synuclein.
a-Synuclein Gene Mutations and Pathologies
in Lewy Body Parkinson’s Disease
Two seminal findings clearly linked a-synuclein to PD:
(1) the discovery that point mutations in SNCA are path-
ogenic for familial forms of PD (Polymeropoulos et al.,
1997); and (2) the demonstration that a-synuclein is the
major component of Lewy bodies and Lewy neurites in
idiopathic or sporadic PD (Spillantini et al., 1997).
Three missense mutations in the SNCA gene, as well
as duplication and triplication of the locus containing
the SNCA gene, have been identified in familial forms
of PD (Forman et al., 2005; Savitt et al., 2006). However,
familial PD caused by a-synuclein missense mutations is
extremely rare, with the A53T mutation originating from
a single common founder, the A30P mutation from a sep-
arate family, and the E46K mutation from yet another
family. Several clinical features may distinguish patients
with the A53T mutation from those with idiopathic PD,
including slightly earlier onset, more rapid disease pro-
gression, lower prevalence of tremor, and noncardinal
features such as dementia and myoclonus earlier in the
disease course. By contrast, patients with the A30P a-
synuclein gene mutation clinically resemble idiopathic
PD. Although no neuropathology reports on patients
with the A30P mutation have been reported, postmor-
tem examination of A53T brains revealed substantia
nigra degeneration and an abundance of a-synucleinLewy bodies and neurites (Kotzbauer et al., 2004). Inter-
estingly, affected E46K family members exhibit the clin-
ical features of dementia and visual hallucinations in ad-
dition to parkinsonism, and neuropathologically, Lewy
bodies were present in neurons of the substantia nigra
as well as the cortex. Thus, this appears to be a familial
form of a sporadic neurodegenerative disorder known
as dementia with Lewy bodies (DLB). However, neuro-
pathologically, DLB is difficult to distinguish from PD
with dementia (PDD), since the burden of Lewy bodies
and neurites is similar in both, but in PDD the dementia
occurs after the onset of parkinsonism, while in DLB the
dementia precedes the movement disorder (McKeith
et al., 2005). Finally, the finding of kindreds with duplica-
tion and triplication of the SNCA gene locus in autoso-
mal dominant PD implicates gene dosage effects in
the pathogenesis of PD (Singleton et al., 2003, Chart-
ier-Harlin et al., 2004). Neuropathological analysis of pa-
tients from some of these kindreds has revealed exten-
sive Lewy body pathology. Taken together, data
showing that a-synuclein gene mutations are inherited
in an autosomal dominant manner and that similara-syn-
uclein pathologies are found in both familial and spo-
radic PD firmly establish a mechanistic link between neu-
rodegeneration, a-synuclein abnormalities, and Lewy
body PD.
Although the missense mutations in a-synuclein are
rare, they may provide insights into pathogenic mecha-
nisms leading to Lewy body formation. Previous studies
have shown that a-synuclein filaments assemble in vitro
from recombinant wild-type proteins, and that these fil-
aments closely resemble those in pathologic inclusions,
while both the A53T and E46K mutations accelerate fibril
formation in test tube assays, suggesting that acceler-
ated polymerization of a-synuclein may be responsible
for disease in patients harboring this mutation (Forman
et al., 2005; Giasson et al., 2004b; Rochet et al., 2004;
Savitt et al., 2006). On the other hand, A30P a-synuclein
has been reported to bind poorly to vesicles compared
with the wild-type protein, although it is not clear how
this is related to disease because the autosomal domi-
nant mode of inheritance suggests a gain of toxic func-
tion for a-synuclein. One possibility is that impaired
binding of A30P a-synuclein to vesicles hinders axonal
transport of the protein, leading to accumulation of,
and aggregation of, a-synuclein in cell bodies and pro-
cesses. Finally, among the multiple other genes that
have been implicated in familial parkinsonism, the un-
derlying neuropathology is incompletely characterized
for most of these familial forms of PD, although individ-
uals with mutations in the LRRK2 gene do develop a-
synuclein pathologies, but the mechanisms to account
for this are not entirely clear (Zimprich et al., 2004).
This notwithstanding, the data on patients with LRRK2
mutations suggest that LRRK2, a protein that contains
a number of well-defined domains, including Ras/
GTPase, tyrosine kinase, WD40, and leucine-rich-repeat
domains, could define a potential pathway that can lead
to a-synuclein Lewy body formation.
a-Synuclein Fibril Formation
Other than missense mutations in a-synuclein, many
other factors and events have been reported to influ-
ence the fibrillization of a-synuclein in vitro, and these
Review
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sions in sporadic PD. Posttranslational modification of
a-synuclein (such as C-terminal truncation and phos-
phorylation), incubation with metals (such as aluminum,
copper, and iron), and oxidative/nitrative challenge
(such as hydrogen peroxide and peroxynitrite treatment)
also may accelerate fibril formation (Giasson et al.,
2004b, Forman et al., 2005, Savitt et al., 2006).
However, oxidation does not always lead to an in-
crease in a-synuclein fibril formation, and dopamine it-
self was shown to inhibit fibrillization, resulting in the
formation of a-synuclein spherical oligomers (Conway
et al., 2001; Rochet, et al., 2004; Norris et al., 2005).
Interestingly, this inhibition is dependent on dopamine
autoxidation, but not on a-synuclein oxidation, and the
dopamine oxidation product dopaminochrome was
identified as a specific inhibitor of a-synuclein fibrilliza-
tion by inducing conformational changes (Norris et al.,
2005). Taken together, these data suggest that dopa-
mine autoxidation can prevent a-synuclein fibrillization
and that decreased dopamine levels in substantia nigra
neurons might promote a-synuclein aggregation in PD.
Models of a-Synuclein Aggregation
and Neurodegeneration
Several a-synuclein animal models have been generated
in flies, worms, and mice that add further support to the
view that pathological a-synuclein is linked to mecha-
nisms of neurodegeneration in PD (Bilen and Bonini,
2005; Feany, 2004; Giasson et al., 2004a). Expression
of wild-type and mutant a-synuclein using promoters
in mice has yielded differing results (Giasson et al.,
2004a). For example, using the platelet-derived growth
factor promoter to drive overexpression of wild-type a-
synuclein results in a mild motor phenotype associated
with dopaminergic nerve terminal loss in the striatum
and inclusion formation in the substantia nigra, cortex,
and hippocampus. However, although these inclusions
contain a-synuclein and ubiquitin, they are unlike the
Lewy bodies of PD because they are granular rather
than fibrillar, and some inclusions are nuclear. Expres-
sion of wild-type or mutant forms of a-synuclein by the
Thy1 promoter also results in a mild motor phenotype
with nonfilamentous accumulation of a-synuclein in var-
ious brain regions. Surprisingly, no differences between
mice expressing wild-type and mutant forms occur.
Mice expressing A53T a-synuclein under control of the
mouse PrP promoter, however, develop filamentous a-
synuclein inclusions, primarily in brainstem and spinal
cord, which correlate with the expression of a severe,
complex motor phenotype leading to paralysis and
death. Although these mice have provided a model
that exhibits a-synuclein inclusion formation and asso-
ciated neuronal dysfunction, the substantia nigra of
these mice is unaffected. However, recent studies of
transgenic mice expressing a truncated form of a-synu-
clein that fibrilizes more readily than the full-length pro-
tein in vitro did show evidence of substantia nigra Lewy
bodies and neurodegeneration (Tofaris et al., 2006).
Thus, a-synuclein transgenic mice provide a compelling
model of PD-like neurodegeneration.
Results from transgenic Drosophila also support
a mechanistic role for pathological a-synuclein in mech-
anisms of PD (Bilen and Bonini, 2005; Feany, 2004). Forexample, panneuronal overexpression of wild-type or
mutant a-synuclein resulted in age-dependent degener-
ation of a subset of dopaminergic neurons, formation of
filamentous a-synuclein inclusions, and locomotor dys-
function. However, bigenic flies expressing human a-
synuclein and heat shock protein 70 (HSP70) or Rab1
GTPase were protected from neurodegeneration de-
spite the formation of Lewy body-like a-synuclein inclu-
sions (Bilen and Bonini, 2005; Cooper et al., 2006).
Accordingly, these Drosophila models exhibit key fea-
tures of PD and may serve as powerful tools in the dis-
covery of genetic factors or pharmacologic agents that
influence the pathogenic process.
Thus, there is overwhelming evidence that a-synu-
clein pathologies play integral roles in the onset and
progression of PD and related disorders. Also, while
the nigrostriatal system is the region that commonly un-
dergoes neurodegeneration in PD, multiple additional
brain regions are always affected in these disorders,
and their clinical manifestations commonly extend be-
yond those attributable to the nigrostriatal system alone
and often include cortical Lewy bodies and Lewy neu-
rites associated with dementia (Forman et al., 2005;
Giasson et al., 2004b; McKeith, et al., 2005).
a-Synuclein Pathogenic Pathways
and Neurodegeneration
How a-synuclein abnormalities lead to neurodegenera-
tion remains to be fully clarified, but several possibilities
have been proposed (Bilen and Bonini, 2005; Cooper
et al., 2006; Cookson, 2005; Forman et al., 2005; Giasson
et al., 2004b; Rochet et al., 2004; Savitt et al., 2006)
as summarized schematically in Figure 1. For example,
a-synuclein localizes to the presynaptic terminal and
binds to lipid membranes, which makes it plausible
that this protein plays a role in the function of synapses
or synaptic turnover. Hence, the sequestration of a-syn-
uclein into aggregates or amyloid fibrils in the disease
state disable it from performing its normal functions.
Moreover, these effects could be amplified if other syn-
aptic proteins that interact with a-synuclein are also se-
questered or trapped in Lewy bodies and Lewy neurites,
thereby resulting in the loss of their critical synaptic
functions. Additionally, the demonstration that Lewy
body pathology is composed of fibrillar a-synuclein,
and that several autosomal dominant mutations in
SNCA lead to enhanced rates of protein fibrillization,
makes it plausible that conformational alterations in
the structure of a-synuclein lead to a gain of neurotoxic
properties by these pathological species of a-synuclein.
However, other investigators have proposed that small,
prefibrillar oligomers of a-synuclein are the toxic spe-
cies leading to neuron dysfunction and degeneration
by forming structures with pore-like morphologies. It is
further hypothesized that these pore-like structures
contribute to cytotoxicity in neurodegenerative dis-
eases by disrupting organelle membranes and altering
permeability that could alter mitochondrial or other or-
ganelle functions. Additionally, misfolding of a-synu-
clein in the endoplasmic reticulum/Golgi network has
been hypothesized to launch a cascade of events culmi-
nating in PD. However, further studies of purified a-syn-
uclein amyloid pores and the effects of pathological
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36Figure 1. Model of a-Synuclein Misfolding and Aggregation and the
Downstream Consequences
Schematic illustration of the stepwise process whereby normal,
highly soluble a-synuclein misfolds and is converted into patholog-
ical oligomers and higher-order aggregates that fibrillize and deposit
into Lewy bodies and Lewy neurites in affected neurons of the
PD brain. The genetic abnormalities mentioned in the text, as well
as poorly understood environmental factors (e.g., pesticides, head
trauma), may accelerate this process and overwhelm the ability of
normal quality-control systems (molecular chaperones, ubiquitin
proteosome system (UPS), phagosome/lysosome system) to pre-
vent or reverse protein misfolding or eliminate proteins that have
misfolded or assembled into pathological aggregates and amyloid
fibrils. Several of the proposed toxic consequences of the accumula-
tion of fibrillar deposits of a-synuclein are illustrated in the lower part
of the figure. The therapeutic interventions discussed in the text are
designed to abrogate the pathways depicted here that lead to the
misfolding, fibrillization, aggregation, and toxicity of a-synuclein
that can culminate in PD and related a-synucleinopathies.a-synuclein on intracellular transport are needed to test
the validity of these hypotheses further.
Thus, although the precise mechanism of pathogene-
sis remains hotly debated, there is strong evidence
implicating increased expression of a-synuclein and
pathologically altered forms of this protein in the patho-
genesis of both familial and sporadic PD. Thus, duplica-
tion as well as triplication of SNCA results in a dose-
dependent increase in the severity and/or age of onset
of PD/PDD (Singleton et al., 2003), while genetic poly-
morphisms in the SNCA gene appear to confer risk for
sporadic PD by increasing the expression of a-synuclein
(Savitt et al., 2006). Thus, genetic mechanisms are impli-
cated in mechanisms of PD by increasing expression,
aggregation, and accumulation of a-synuclein in the
CNS (Giasson et al., 2004b; Forman et al., 2005; Savitt,
et al., 2006; Skovronsky et al., 2006).
However, environmental factors may also play a cru-
cial role in the pathogenesis of a-synucleinopathies,
and epidemiological studies suggest an association of
PD with environmental toxins such as pesticides. In-
deed, chronic systemic treatment of rats with rotenone,
a pesticide known to inhibit mitochondria, causes selec-
tive nigrostriatal dopaminergic degeneration with asso-
ciated inclusions containing fibrillar a-synuclein (Green-
amyre and Hastings, 2004; Savitt et al., 2006). Thus,
rotenone treatment may induce an increase in oxidative
stress in the dopaminergic neurons, which in turn
may facilitate fibrillization of a-synuclein, providing a
link between oxidative stress and pathogenesis of
a-synucleinopathies.
Accordingly, based on the data summarized above
and in other recent reviews (Bilen and Bonini, 2005;
Rochet, et al., 2004; Savitt et al., 2006; Skovronsky
et al., 2006), there are multiple reasons to target path-
ological species of a-synuclein for the discovery of
novel disease-modifying therapies for PD and related
a-synucleinopathies. A list of the most compelling rea-
sons to embark on PD drug discovery that focuses on
pathways leading to a-synuclein pathologies follows
here, and some of these are discussed in further detail
below:
1) Mutations/multiplications in theSNCA gene cause
familial PD/PDD/DLB.
2) Lewy bodies and Lewy neurites are hallmark PD/
PDD/DLB amyloid inclusions detected by a-synu-
clein-specific antibodies.
3) Epitope mapping demonstrates that regions
spanning the entire a-synuclein molecule are
present in Lewy bodies.
4) Insoluble, filamentous a-synuclein aggregates in
Lewy bodies and Lewy neurites contain abnor-
mally nitrated, phopshorylated, and ubiquitinated
residues.
5) a-Synuclein filaments are recovered from PD/
PDD/DLB brains as well as from Lewy bodies pu-
rified from these brains.
6) Recombinant a-synuclein forms Lewy body-like
amyloid fibrils.
7) a-Synuclein single transgenic mice/worms/flies
develop a neurodegenerative disease with fila-
mentous a-synuclein amyloid deposits.
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in flies and b-synuclein with a-synuclein in mice
ameliorates the disease phenotype, while induc-
tion of heat shock proteins (HSPs) with geldana-
mycin in a-synuclein transgenic flies attenuates
degeneration of Lewy body-containing neurons.
Targeting a-Synuclein-Mediated Neurodegeneration
for Parkinson’s Disease Drug Discovery
It is becoming increasingly evident that several ap-
proaches to drug discovery appear compelling based
on the current understanding of a-synuclein-mediated
mechanisms of neurodegeneration (Figure 1). For exam-
ple, inhibition of a-synuclein aggregation is an attractive
target for drug development, and several groups have
identified small-molecule and peptide-based inhibitors
of aggregation (Rochet, et al., 2004; Savitt et al., 2006;
Skovronsky et al., 2006). Interestingly, a number of cat-
echolamines, including dopamine, have been found to
inhibit a-synuclein fibrillization, and the inhibitory activ-
ity of dopamine depends on its oxidation and leads to
accumulation of a-synuclein protofibrils (Norris et al.,
2005; Rochet et al., 2004). Hence, this link between do-
pamine and a-synuclein provides insights into the po-
tential mechanisms underlying the selective vulnerabil-
ity of dopaminergic neurons in PD, although many
types of neurons other than those that are dopaminer-
gic, as well as astrocytes and oligodendroglial cells,
also are selectively affected by accumulations of
a-synuclein inclusions.
Moreover, the ameliorative effects of HSPs on the PD
phenotype in model systems discussed above were ex-
tended by followup studies showing that treatment of
transgenic a-synuclein-expressing flies with the drug
geldanamycin protects neurons against a-synuclein
toxicity through augmenting chaperone activity (Bilen
and Bonini, 2005). An alternative approach would be to
harness other normal cellular mechanisms that counter-
act the accumulation of intracellular misfolded or con-
formationally altered proteins, including normal proteo-
lytic pathways, the ubiquitin proteasome system, and
autophagic system (Cuervo et al., 2004). Finally, while
the biochemical signatures of pathological a-synuclein
are abnormal protein phosporylation, ubiquitination, in-
solubility and aggregation, the abnormal phosphoryla-
tion and ubiquitination of a-synuclein have not yet
been shown to be required for fibrillization (Giasson
et al., 2004b). Nonetheless, abnormal phosphorylation
may be a target for the discovery of disease-modifying
therapies of PD, since this posttranslational modification
may contribute to stabilizing a-synuclein aggregates.
However, a major impediment to conducting cost-
effective and informative clinical trials of potential dis-
ease-modifying therapies for PD and related a-synuclei-
nopathies is the absence of robust biomarkers for both
early diagnosis of these disorders when therapy is likely
to have the greatest impact and monitoring the re-
sponses of patients to new therapeutic interventions in
clinical trials. A challenge to overcoming this obstacle
is the complexity of neurodegenerative movement dis-
orders and the overlap of a-synucleinopathies with other
diseases, including Alzheimer’s disease (AD), the most
common subtype of which is the Lewy body variant ofAD. As in the AD field, which is at the vanguard of neuro-
degenerative disease biomarker research (Thal et al.,
2006), all biomarkers for PD and related a-synuclei-
noapthies should be developed and validated based
on criteria similar to those proposed by the Work Group
On Biological Markers of Alzheimer’s Disease (Ronald
and Nancy Regan Institute, 1998). The consensus report
from this group of biomarker experts specified that ideal
AD biomarkers should be linked to fundamental features
of AD neuropathology, be validated in neuropathologi-
cally confirmed AD cases, be able to detect AD early in
its course and distinguish it from other dementias, and
be reliable, noninvasive, simple to perform, and inex-
pensive. Furthermore, it was recommended that all AD
biomarkers undergo evaluation of their sensitivity, spec-
ificity, prior probability, positive predictive value, and
negative predictive value, as well as undergo validation
by independent groups who publish their findings in
peer-reviewed journals. Finally, to be informative for di-
agnosis, it was recommended that biomarkers have
a sensitivity and specificity of >85%. The same recom-
mendations of this AD biomarker work group should
also be applied to PD biomarkers, which could be
grounded in a better understanding of a-synuclein-
mediated neurodegeneration. Indeed, there are emerg-
ing data to suggest that the measurement of normal or
pathological a-synuclein in cerebrospinal fluid or blood
could lead to the development of diagnostic tests (To-
kuda et al., 2006). However, while hypothesis-driven
candidate biomarkers such as normal and abnormal a-
synuclein proteins should be a major focus of PD bio-
marker research, it is timely to pursue the identification
of biomarkers using unbiased strategies based on pro-
teomics or related technologies (Abdi et al., 2006).
These significant challenges to PD drug discovery
notwithstanding, the advances in PD research reviewed
here suggest that therapeutic agents designed to inhibit
or reverse the fibrillization and aggregation of a-synu-
clein in PD and related a-synucleinopathies could have
potential disease-modifying effects. The realization of
this PD drug discovery goal would certainly revolution-
ize the treatment of PD for the second time since the in-
troduction of L-dopa for the symptomatic therapy of PD
50 years ago, thereby offering prospects for not only ar-
resting and/or reversing the progression of PD, but also
preventing the onset of this and related neurodegenera-
tive a-synucleinopathies.
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